The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Five regions in the U.S. have been selected to implement a new preventive health initiative to improve care for people with a cluster of chronic conditions known as cardiovascular-kidney-metabolic ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidney disease, type 2 diabetes and obesity.[1] This cluster of chronic ...

American Heart Association initiative aims to improve care for people in Atlanta; Baton Rouge, La.; Washington, D.C.; Maryland; San Diego and Ohio who have a cluster of conditions called cardiovascula ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...